| __timestamp | Grifols, S.A. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 1656170000 | 179279000 |
| Thursday, January 1, 2015 | 2003565000 | 186359000 |
| Friday, January 1, 2016 | 2137539000 | 171785000 |
| Sunday, January 1, 2017 | 2166062000 | 208136000 |
| Monday, January 1, 2018 | 2437164000 | 198405000 |
| Tuesday, January 1, 2019 | 2757459000 | 224169000 |
| Wednesday, January 1, 2020 | 3084873000 | 245044000 |
| Friday, January 1, 2021 | 2970522000 | 252314000 |
| Saturday, January 1, 2022 | 3832437000 | 268225000 |
| Sunday, January 1, 2023 | 4269276000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Data in motion
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. Over the past decade, Grifols, S.A. and Taro Pharmaceutical Industries Ltd. have showcased contrasting trajectories in their cost of revenue. Grifols, S.A., a leader in the blood plasma sector, has seen its cost of revenue soar by approximately 158% from 2014 to 2023, reflecting its aggressive expansion and investment strategies. In contrast, Taro Pharmaceutical, known for its generic drug production, has maintained a more stable cost structure, with a modest increase of around 70% over the same period.
The data reveals a fascinating narrative of growth and stability, with Grifols' costs peaking in 2023, while Taro's efficiency remains consistent. This comparison highlights the diverse strategies employed by pharmaceutical companies to navigate market challenges and opportunities.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: GSK plc and Grifols, S.A.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Who Generates Higher Gross Profit? Grifols, S.A. or Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE